Natalia Aptsiauri

6PUBLICATIONS
13CO-AUTHORS
Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 08, 2025
Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities.

María Antonia Garrido, Alba Navarro-Ocón, Víctor Ronco-Díaz

|Oct 20, 2024
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.

Marta Molina-Alejandre, Francisco Perea, Virginia Calvo

|Jul 21, 2022
The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes.

Natalia Aptsiauri, Federico Garrido

|Mar 26, 2022
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.

Alba Navarro-Ocón, Jose L Blaya-Cánovas, Araceli López-Tejada

|Oct 23, 2021
Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer.

Maria Antonia Garrido, Francisco Perea, Jose Ramon Vilchez

|Jul 24, 2021
Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.

Hernani Gil-Julio, Francisco Perea, Antonio Rodriguez-Nicolas

Pageof 1